✦ LIBER ✦

Tu2038 All Oral Fixed-dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: The Phase 3 ION-1 Study

✍ Scribed by Jacobson, Ira M.; Marcellin, Patrick; Mangia, Alessandra; Kwo, Paul Y.; Foster, Graham; Buti, Maria; Brau, Norbert; Muir, Andrew J.; Yang, Jenny C.; Mo, Hongmei; Ding, Xiao; Pang, Phil; Symonds, William T.; McHutchison, John G.; Zeuzem, Stefan; Afdhal, Nezam H.

Book ID: 122194154
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 46 KB
Volume: 146
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(14)63284-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

O164 ALL ORAL FIXED-DOSE COMBINATION SOF

O164 ALL ORAL FIXED-DOSE COMBINATION SOFOSBUVIR/LEDIPASVIR WITH OR WITHOUT RIBAVIRIN FOR 12 OR 24 WEEKS IN TREATMENT-NAIVE GENOTYPE 1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-1 STUDY

✍ Mangia, A.; Marcellin, P.; Kwo, P.; Foster, G.R.; Buti, M.; Bräu, N.; Muir, A.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 170 KB

O109 ALL ORAL FIXED-DOSE COMBINATION SOF

O109 ALL ORAL FIXED-DOSE COMBINATION SOFOSBUVIR/LEDIPASVIR WITH OR WITHOUT RIBAVIRIN FOR 12 OR 24 WEEKS IN TREATMENT-EXPERIENCED GENOTYPE 1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-2 STUDY

✍ Afdhal, N.; Reddy, R.K.; Pockros, P.; Di Bisceglie, A.M.; Arora, S.; Yang, J.C.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 151 KB

236 All Oral Fixed-Dose Combination Sofo

236 All Oral Fixed-Dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Experienced Genotype 1 HCVInfected Patients: The Phase 3 Ion-2 Study

✍ Kwo, Paul Y.; Reddy, K. Rajender; Pockros, Paul J.; Di Bisceglie, Adrian M.; Aro 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 361 KB

O56 SOFOSBUVIR/LEDIPASVIR WITH AND WITHO

O56 SOFOSBUVIR/LEDIPASVIR WITH AND WITHOUT RIBAVIRIN FOR 8 WEEKS COMPARED TO SOFOSBUVIR/LEDIPASVIR FOR 12 WEEKS IN TREATMENT-NAÏVE NON-CIRRHOTIC GENOTYPE-1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-3 STUDY

✍ Kowdley, K.V.; Stuart, G.C.; Reddy, R.K.; Rossaro, L.; Bernstein, D.E.; An, D.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 172 KB

764 Sofosbuvir/Ledipasvir With and Witho

764 Sofosbuvir/Ledipasvir With and Without Ribavirin for 8 Weeks Compared to Sofosbuvir/Ledipasvir for 12 Weeks in Treatment-Naive Non-Cirrhotic Genotype-1 HCV-Infected Patients: The Phase 3 Ion-3 Study

✍ Kowdley, Kris V.; Gordon, Stuart C.; Reddy, K. Rajender; Rossaro, Lorenzo; Berns 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 166 KB

6 ALL ORAL THERAPY WITH SOFOSBUVIR + RIB

6 ALL ORAL THERAPY WITH SOFOSBUVIR + RIBAVIRIN FOR 12 OR 16 WEEKS IN TREATMENT EXPERIENCED GT2/3 HCV-INFECTED PATIENTS: RESULTS OF THE PHASE 3 FUSION TRIAL

✍ Nelson, D.R.; Feld, J.; Kowdley, K.V.; Al-Assi, M.T.; Lin, M.; Mo, H.; McNally, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 74 KB